Compare CLRO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLRO | BCDA |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 13.6M |
| IPO Year | 2018 | N/A |
| Metric | CLRO | BCDA |
|---|---|---|
| Price | $5.34 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 8.2M | 588.4K |
| Earning Date | 05-18-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.59 | N/A |
| 52 Week Low | $2.71 | $0.78 |
| 52 Week High | $16.50 | $2.37 |
| Indicator | CLRO | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 41.61 |
| Support Level | $4.01 | $0.81 |
| Resistance Level | $5.62 | $1.29 |
| Average True Range (ATR) | 2.51 | 0.09 |
| MACD | -0.38 | -0.01 |
| Stochastic Oscillator | 0.79 | 14.32 |
ClearOne Inc is a communications solutions company, which is engaged in designing, developing, and selling conferencing, collaboration, streaming, and digital signage solutions for audio, video, and visual communication. It sells its commercial products to end-users predominantly through a network of independent distributors, who in turn sell its products to dealers, systems integrators, and other resellers. Its products include DSP mixers, amplifiers, Video walls, professional cameras, and professional microphones among others. Geographically the firm has its business presence across the United States and international markets.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).